The upcoming presentations focus on expanding the clinical understanding of migraine beyond mere attack frequency. For the approved treatment Vyepti (eptinezumab), new analyses from the RESOLUTION and SUNRISE trials examine patient-centered outcomes, including workplace productivity, acute medication reliance, and the psychological impact of chronic migraine and medication-overuse headache.
Lundbeck is also placing a spotlight on bocunebart, a monoclonal antibody designed to inhibit the pituitary adenylate cyclase-activating polypeptide (PACAP) pathway. As a late-breaker presentation, the PROCEED trial data will offer insight into whether this distinct mechanism can provide relief for patients who have failed to respond to previous preventive treatments. According to Dr. Andrew Blumenfeld of Cedars Sinai Los Angeles, this research represents a critical step in addressing the needs of patients who remain underserved by current therapeutic options.
Comments (0)
No comments yet. Be the first!